Full-Time

Director – Trade and Distribution

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$210k - $253kAnnually

Senior, Expert

San Carlos, CA, USA

Position is based out of headquarters in Redwood City, CA.

Category
Supply Chain Management
Transportation & Distribution
Warehouse Operations
Operations & Logistics
Requirements
  • Bachelor’s degree required with 7-8+ years of experience in market access operations in pharmaceuticals or biopharma.
  • Experience in new product launches.
  • Experience with day-to-day management of 3PL and other distribution partners.
  • Deep understanding of US drug channel dynamics.
  • Experience with 844/867/852 data and inventory reporting and systems.
  • Track record of being a collaborative team player, and adaptive to meet the needs of a growing business.
  • Strong problem solver with experience leveraging a variety of data sources, platforms, and analytical vendors.
  • Excellent organizational skills and an ability to prioritize effectively to deliver results within reasonably established timelines.
  • Ability to represent Revolution Medicines well: strong interpersonal skills including verbal and written communication.
  • Ability to travel up to 25%.
Responsibilities
  • Establishes and manage strong relationships with key distribution partners, including 3PL vendor, specialty distributors, and specialty pharmacies.
  • Oversees 3PL vendor.
  • Coordinates across Supply Chain, Information Systems (IS), Quality, Finance and Commercial to prepare for launching RevMed’s first medicine, including initial stocking plan and distribution data strategy.
  • Partners closely with Finance and government pricing vendor to ensure shipment data, chargebacks, and returns are correctly loaded in internal data reporting systems.
  • Partners with finance to review chargebacks for accuracy and eligibility in accordance with contract terms.
  • Develops return policy and approve returns that meet policy requirements once product launches.
  • Leads regular business reviews with distribution partners to ensure KPIs and service level agreements (SLAs) are being met and identify opportunities to improve processes.
  • Works with Sr. Director to refine the distribution strategy if needed for any future approved indication(s) and/or new product launches.

Revolution Medicines develops targeted treatments for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to specifically inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses exclusively on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?